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Introduction: High-sensitivity cardiac troponin I(hs-TnI) and T levels(hs-TnT) are sensitive biomarkers of
cardiomyocyte turnover or necrosis. Prior studies of the predictive role of hs-TnT in type 2 diabetes mellitus(T2DM)
patients have yielded conflicting results. This study aimed to determine whether hs-TnI, which is detectable in a
higher proportion of normal subjects than hsTnT, is associated with a major adverse cardiovascular event(MACE) in
T2DM patients.
Methods and results: We compared hs-TnI level in stored serum samples from 276 consecutive patients (mean
age 65 ± 10 years; 57% male) with T2DM with that of 115 age-and sex-matched controls. All T2DM patients were
prospectively followed up for at least 4 years for incidence of MACE including heart failure(HF), myocardial
infarction(MI) and cardiovascular mortality. At baseline, 274(99%) patients with T2DM had detectable hs-TnI, and 57
(21%) had elevated hs-TnI (male: 8.5 ng/L, female: 7.6 ng/L, above the 99th percentile in healthy controls). A total of
43 MACE occurred: HF(n = 18), MI(n = 11) and cardiovascular mortality(n = 14). Kaplan-Meier analysis showed that an
elevated hs-TnI was associated with MACE, HF, MI and cardiovascular mortality. Although multivariate analysis
revealed that an elevated hs-TnI independently predicted MACE, it had limited sensitivity(62.7%) and positive
predictive value(38.5%). Contrary to this, a normal hs-TnI level had an excellent negative predictive value(92.2%) for
future MACE in patients with T2DM.
Conclusion: The present study demonstrates that elevated hs-TnI in patients with T2DM is associated with
increased MACE, HF, MI and cardiovascular mortality. Importantly, a normal hs-TnI level has an excellent negative
predictive value for future adverse cardiovascular events during long-term follow-up.
Keywords: Type 2 diabetes mellitus, High-sensitivity troponin I outcomeIntroduction
Cardiac troponin is a key biomarker for the diagnosis of
myocardial infarction (MI) and provides important prog-
nostic information in patients who present with acute
coronary syndrome [1-3]. High-sensitivity cardiac tropo-
nin levels T (hs-TnT) and I (hs-TnI) are more sensitive
biomarkers that can detect troponin below the clinical
threshold, and reflect subtle cardiomyocyte turnover or* Correspondence: hftse@hkucc.hku.hk
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unless otherwise stated.necrosis. These novel biomarkers have been shown to be
associated with adverse clinical and cardiovascular
events in the general population [4-7], and in patients
with congestive heart failure [8], acute coronary syn-
drome [9] and stable atherosclerotic disease [10,11].
Recent studies have demonstrated that patients with
type 2 diabetes mellitus (T2DM) without prior cardiovas-
cular disease [12] and a high hbA1c% had elevated
hs-TnT [13]. It has been proposed that chronic hypergly-
cemia contributes to subtle myocardial injury as detected
by hs-TnT that is beyond its effects on development of
clinical atherosclerotic coronary disease [13]. The clinical
implications of an elevated high-sensitivity troponin assay. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Hallen et al. [14] showed that elevated hs-TnT was fre-
quently detected in diabetic patients but did not predict
future adverse outcomes over a 2 year follow-up period.
Conversely, recent results from the Women’s Health
Study demonstrated that a detectable level of hs-TnT was
associated with increased cardiovascular morbidity and
mortality in diabetic women [12]. Compared with hs-TnT
measurement, higher proportions of normal subjects have
a detectable level of hs-TnI, making it a more sensitive
assay for subtle myocardial damage [15]. Currently, there
are no data on the predictive value of hs-TnI in patients
with T2DM. This study sought to investigate whether an
elevated hs-TnI is associated with a major adverse cardio-
vascular event (MACE) in patients with T2DM.
Methods
Study population
Consecutive T2DM patients (n = 293) as defined by
World Health Organization criteria [16,17] on stable
hypoglycemic and cardiovascular medication for at least
3 months were recruited from the medical outpatient
clinic. Exclusion criteria included recent acute coronary
syndrome, stroke, coronary intervention, hospitalization
for cardiac surgery or heart failure within the last
6 months, dilated cardiomyopathy, significant valvular
heart disease, chronic atrial fibrillation, New York Heart
Association class III/IV heart failure, estimated glomeru-
lar filtration rate (eGFR) <30 mL/min per 1.73 m2, and
refusal to participate (n = 17). A total of 276 patients
with T2DM were consequently eligible for this study.
During the study period, 115 age- and sex-matched
Chinese controls without T2DM or established cardio-
vascular disease were recruited from a community
health screening programme. Written informed consent
was obtained from all study subjects. The study was ap-
proved by the Institutional Review Board of the Univer-
sity of Hong Kong/Hospital Authority Hong Kong West
Cluster and was conducted according to the Declaration
of Helsinki. This study is part of the Chinese Diabetic
Heart Study (CDATS) to evaluate cardiovascular mani-
festation of Chinese patients with T2DM, in an attempt
to evaluate the pathophysiology and potential therapeu-
tics in these patients.
Clinical parameters
Baseline demographic data, clinical characteristics and
blood sampling were obtained on the same day from all
study subjects. Blood pressure, body weight, body height,
and body mass index (BMI) were also measured. Hyper-
tension was defined as resting systolic or diastolic blood
pressure >140 mmHg or >90 mm Hg, respectively, at two
different clinic visits or the prescription of antihyperten-
sive medication. Hypercholesterolemia was defined asfasting total plasma cholesterol ≥4.9 mmol/liter or the
prescription of statins. Smoking status was recorded as
ever smoker (past or current) or nonsmoker. Duration of
T2DM and data on prescribed oral hypoglycemic agents
and insulin therapy were retrieved from patients’ medical
records.
Serum HbA1c, total cholesterol, triglyceride, high-
density lipoprotein cholesterol and low-density lipoprotein
cholesterol levels, fasting glucose, and HbA1c were mea-
sured in all subjects in a fasting venous blood sample [18].
Serum creatinine levels were used to assess eGRF calcu-
lated with the Modified Diet in Renal Disease Equation
[19]. Serum level of hs-TnI was determined using Chemo-
luminescent Microparticule ImmunoAssay (Architect
i1000SR AbbottW, Paris, France). The level of detection is
1.2 ng/L according to the manufacturer’s instruction and
above such is considered to be a detectable hs-TnI. An
elevated hs-TnI was defined as plasma level greater than
the 99th percentile based on the hs-TnI of an age-matched
healthy control for both genders, respectively.
Follow-up
All patients were followed up for a minimum of 4 years.
Outcome of patients was retrieved from the inter-hospital
computer system or by telephone interview. The MACE
was a composite endpoint of heart failure requiring hos-
pital admission, myocardial infarction and cardiovascular
mortality. The definition of MI was based on the presence
of typical chest pain, elevated cardiac enzyme levels, and
typical electrocardiogram changes [1].
Statistical analysis
Data are expressed as mean ± standard deviation for
continuous variables and frequencies or proportions for
categorical variables. Continuous demographic variables
of the two groups were compared using the Mann-
Whitney U test and categorical demographic variables
compared using Pearson Chi-square test or the Fisher’s
exact test if at least one cell had an expected cell count
below five. Cumulative incidence of the first occurrence
of MACE for patients with elevated hs-TnI and normal
hs-TnI level was estimated using the Kaplan-Meier
method and compared with the log-rank test. First
occurrence of heart failure, myocardial infarction and
cardiovascular mortality was evaluated. Multivariate ana-
lyses for MACE, heart failure, myocardial infarction and
cardiovascular mortality were performed using Cox re-
gression models.
Three levels of adjustment were made: (1) demographics
(age and gender); (2) demographic factors, cardiovascular
risk factors (hypertension, hyperlipidemia, smoking his-
tory, coronary heart disease); (3) demographic factors, risk
factors, cardiovascular risk factors and eGFR level. All
statistical analyses were performed using the statistical
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USA). All P values reported are 2-sided for consistency. A
P value <0.05 was considered statistically significant.
Results
Clinical characteristics
Baseline characteristics of patients with T2DM and con-
trols are shown in Table 1. Patients with T2DM had a
higher BMI, were more likely to be a smoker and had a
history of hypertension and hypercholesterolemia com-
pared with controls. In addition, the eGFR was lower,
and fasting glucose and HbA1c% were higher.
Serum level of hs-TnI
The proportion of patients with T2DM and serum level of
hs-TnI at or above the limit of detection (1.2 ng/L) was
similar to controls (274/276, 99.3% versus 114/115, 99.1%,
P = 1.0). The median serum level of hs-TnI in patients
with T2DM was significantly higher (median [interquatile
range]: 4.8 [3.2-8.4 ng/L] versus 2.9 [2.2-3.9 ng/L],
P < 0.01).
In this study, the 99th percentile value of serum hs-TnI
level in male and female control subjects was 8.5 ng/L
and 7.6 ng/L, respectively. These serum levels were de-
fined as the cut-off values for elevated serum hs-TnI.Table 1 Baseline demographics of type 2 diabetes mellitus (T
Troponin I (hs-TnI) and controls
Parameters T2DM (n = 276) Controls (n = 115) P
Age, years 64.4 ± 10.0 63.4 ± 7.9 0
Male, % (n) 154 (56) 53 (61) 0
Body mass index, kg/m2 25.5 ± 3.5 23.6 ± 3.4 <
Current smoker, % (n) 33 (92) 6 (7) <
Hypertension, % (n) 70 (194) 15 (17) <
Hypercholesterolemia, % (n) 63 (174) 30 (26) <
Duration of DM, years 9.8 ± 7.6 – –
CAD, % (n) 29 (113) – –
Total cholesterol, mmol/L 4.6 ± 1.0 5.0 ± 0.9 <
Triglycerides, mmol/L 1.6 ± 1.8 1.3 ± 0.8 <
High density lipoprotein, mmol/L 1.3 ± 0.8 1.5 ± 0.4 <
Low density lipoprotein, mmol/L 2.7 ± 0.8 3.0 ± 0.7 <
eGFR, mL/min per 1.73 m2 81.8 ± 19.3 85.8 ± 14.1 0
Fasting glucose, mmol/L 7.6 ± 2.3 5.1 ± 0.5 <
HbA1c, % 7.8 ± 1.4 5.9 ± 0.4 <
Medication
Insulin, % (n) 14 (38) 0 (0) <
Aspirin, % (n) 40 (109) 0 (0) <
ACEI/ARB, % (n) 60 (166) 1 (1) <
Statin, % (n) 42 (115) 2 (2) <
Abbreviation:
ACEI = angiotensin converting enzyme inhibitor; ARB = angiotensin receptor blockerBased on these cut-off values, 70 (25.4%) patients with
T2DM had an elevated serum hs-TnI level. As shown in
Table 1, T2DM patients with elevated serum hs-TnI level
were older, more likely to be male, smoke, have a history
of hypertension and coronary artery disease, low eGFR
level, and be treated with aspirin, angiotensin converting
enzyme inhibitor/angiotensin receptor blocker and statin
compared with T2DM patients with a normal serum hs-
TnI level. Univariate analysis showed that elderly age,
male gender, smoking, a history of hypertension and cor-
onary artery disease and low eGFR were associated with
elevated serum hs-TnI level in T2DM patients. Multi-
variate analysis nonetheless revealed that only history of
coronary artery disease and low eGRF were independ-
ently associated with an elevated serum hs-TnI level
(Table 2).
Clinical outcomes
The median follow-up period was 4.9 years (interquartile
range, 3.7 to 5.6 years), and none of the control subjects
developed MACE. A total of 43 patients with T2DM de-
veloped MACE during this follow-up period. Among
those MACEs, there were 18 heart failure events (12 dia-
stolic heart failure, 6 systolic heart failure), 11 myocar-
dial infarctions and 14 cases of cardiovascular mortality2DM) patients with and without elevated high sensitivity
value Elevated hs-TnI (n = 70) Normal hs-TnI (n = 206) P value
.29 68.6 ± 9.2 62.9 ± 9.9 <0.01
.35 70 (49) 30 (21) <0.01
0.01 25.4 ± 3.5 25.6 ± 3.6 0.72
0.01 49 (34) 28 (58) <0.01
0.01 89 (62) 132 (64) <0.01
0.01 70 (49) 61 (125) 0.10
10.2 ± 8.7 9.7 ± 7.3 0.67
60 (42) 35 (71) <0.01
0.01 4.5 ± 1.1 4.7 ± 1.0 0.15
0.01 1.6 ± 1.1 1.6 ± 1.9 0.99
0.01 1.2 ± 0.4 1.3 ± 0.4 0.16
0.01 2.6 ± 0.8 2.7 ± 0.8 0.55
.03 72.0 ± 18.7 84.2 ± 18.7 <0.01
0.01 7.6 ± 2.8 7.6 ± 2.1 0.96
0.01 8.1 ± 1.7 7.7 ± 1.4 0.21
0.01 19 (13) 12 (25) 0.13
0.01 56 (39) 34 (70) <0.01
0.01 77 (54) 54 (112) <0.01
0.01 57 (40) 37 (75) <0.01
; CAD = coronary artery disease; eGFR = estimated glomerular filtration rate.
Table 2 Predictors for high-sensitivity troponin I in patients with type 2 diabetes mellitus
Univariate analysis Multivariate analysis
Variables β 95% CI P value β 95% CI P value
Age 1.07 1.03-1.10 <0.01 1.02 0.97-1.06 0.46
Male gender 2.24 1.26-4.01 <0.01 2.08 0.82-5.28 0.12
Body mass index 0.99 0.91-1.07 0.72
Smoker 2.41 1.38-4.21 <0.01 1.58 0.64-3.87 0.32
Hypertension 4.35 1.97-9.57 <0.01 2.21 0.90-5.44 0.09
Duration of disease 1.01 0.97-1.05 0.64
History of CAD 2.85 1.63-4.98 <0.01 2.93 1.33-6.44 <0.01
Total Cholesterol 0.80 0.60-1.08 0.14
Triglyceride 0.99 0.84-1.19 0.99
High density lipoprotein 0.51 0.20-1.27 0.15
Low density lipoprotein 0.89 0.60-1.31 0.54
eGFR 0.97 0.95-0.98 <0.01 0.97 0.95-0.99 0.02
Fasting glucose 0.99 0.88-1.13 0.96
HbA1c 1.17 0.94-1.45 0.16
Insulin 1.65 0.79-3.44 0.18
Abbreviations as in Table 1.
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sudden death). For the whole population, the annual
MACE event rate was 3.3%, heart failure event rate was
1.4%, myocardial infarction event rate was 1.3% and car-
diovascular mortality event rate was 1.0%. More import-
antly, T2DM patients with elevated hs-TnI had a higher
annual event rate for MACE (9.3% vs. 1.6%), heart fail-
ure (3.8% vs.0.6%), myocardial infarction (1.5% vs.0.6%)Figure 1 Kaplan-Meier Curve reflecting cumulative proportion of pati
cardiovascular events [MACE]; (b) heart failure; (c) myocardial infarctiand cardiovascular mortality (3.5% vs. 0.2%) than those
T2DM patients with normal serum hs-TnI level (P <
0.01). As shown in Figure 1, T2DM patients with ele-
vated serum level of hs-TnI had a significantly higher
risk for MACEs (Hazard ratio [HR] 8.9, 95% confidence
interval [CI] 4.3-18.4 , P < 0.01); heart failure (HR 19.6,
95% CI 4.0-40.6 , P < 0.01), and cardiovascular mortality
(HR 17.1 95% CI 5.3-55.5 , P < 0.01), but not myocardialents with type 2 diabetes mellitus free of (a) major adverse
on; and (d) cardiovascular mortality.
Yiu et al. Cardiovascular Diabetology 2014, 13:63 Page 5 of 8
http://www.cardiab.com/content/13/1/63infarction (HR 2.9, 95% CI 0.7-11.5, P = 0.14) than those
with normal serum hs-TnI level during follow-up.
Predictive value of serum hs-TnI level
Cox proportional hazard models were used to evaluate
the impact of elevated serum hs-TnI level on adverse
clinical outcome (Table 3). In both the unadjusted model
and adjusted models for demographic factors and car-
diovascular risk factors, an elevated serum hs-TnI level
in patients with T2DM was predictive of MACE, heart
failure and cardiovascular mortality. Even after adjusting
for demographic factors, cardiovascular risk factors and
eGFR, an elevated serum hs-TnI level remained an inde-
pendent predictor for MACE and heart failure.
In order to evaluate the clinical application of hs-TnI
level, the sensitivity, specificity, positive predictive value
and negative predictive value of an elevated serum hs-
TnI level was determined to predict future MACE. In
patients with T2DM, an elevated serum hs-TnI level had
a high specificity (84.4%) but limited sensitivity (62.7%)
and positive predictive value (38.5%) for MACE. Con-
versely, a normal serum hs-TnI level had an excellentTable 3 Association of elevated high-sensitivity troponin I (hs
events (MACE), heart failure, myocardial infarction and cardio
Variables
MACE
Unadjusteda
Adjusted for demographic factorsb
Adjusted for demographic, cardiovascular risk factorsc
Adjusted for demographic, cardiovascular risk factors and eGFRd
Heart failure
Unadjusteda
Adjusted for demographic factorsb
Adjusted for demographic, cardiovascular risk factorsc
Adjusted for demographic, cardiovascular risk factors and eGFRd
Myocardial infarction
Unadjusteda
Adjusted for demographic factorsb
Adjusted for demographic, cardiovascular risk factorsc
Adjusted for demographic, cardiovascular risk factors and eGFRd
Cardiovascular mortality
Unadjusteda
Adjusted for demographic factorsb
Adjusted for demographic, cardiovascular risk factorsc
Adjusted for demographic, cardiovascular risk factors and eGFRd
Abbreviations as in Table 1; HR = hazard ratio.
aAll models additionally adjusted for hs-TnI.
bAdjusted for age and gender.
cAdjusted for modelb and hypertension, hyperlipidemia, smoking history and coron
dAdjusted for modelc and eGFR.negative predictive value (92.2%) for future MACE in
T2DM patients.
Discussion
The present study demonstrates that up to 25% of
T2DM patients without clinical evidence of active car-
diovascular disease have ongoing subtle myocardial in-
jury/necrosis as detected by an elevated serum level of
hs-TnI. An elevated serum hs-TnI level in patients with
T2DM, above the gender-specific cut-off value in the
control population, was associated with a more than 2-
fold increase in the adjusted risk of MACE. Importantly,
a normal serum hs-TnI level had an excellent negative
predictive value for future adverse cardiovascular out-
come in patients with T2DM after up to 4 years of
follow-up.
Elevated high sensitivity troponin level suggested myo-
cardial injury that has been shown to be related with ar-
terial stiffening in patients with T2DM [20]. In addition
to detect subtle myocardial necrosis, its clinical value
has also been shown to provide important prognostic in-
formation in various groups of patients. Several studies-TnI) with subsequent major adverse cardiovascular
vascular mortality
Univariate analysis
HR 95% CI P value
5.69 3.05-10.62 <0.01
3.81 2.01-7.24 <0.01
3.70 1.91-7.18 <0.01
2.85 1.15-7.03 0.02
7.21 2.70-19.25 <0.01
4.98 1.80-13.83 <0.01
4.88 1.71-13.96 <0.01
4.88 1.12-21.31 0.03
2.45 0.72-8.31 0.15
1.70 0.48-5.99 0.41
1.34 0.36-5.04 0.67
0.84 0.12-6.17 0.87
15.90 3.52-71.87 <0.01
10.0 2.13-47.19 <0.01
9.14 1.92-43.60 <0.01
6.19 0.50-76.59 0.16
ary heart disease.
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diovascular events by hs-TnT in the general population
[4,5,21], patients with stable and unstable angina [22],
acute coronary syndrome [23] and heart failure [24].
Similarly, hs-TnI has been shown to provide prognostic
information in the general population [6], patients with
stable atherosclerotic disease [10,11] and acute coronary
syndrome [25]. Although these studies have consistently
demonstrated that high sensitivity troponin can predict
future adverse cardiovascular events in different groups
of patients, its prognostic value has not been well stud-
ied in patients with T2DM. A recent report from the
Women Health Study demonstrated that among diabetic
women without cardiovascular disease (n = 512), a de-
tectable hs-TnT was associated with total cardiovascular
disease (adjusted hazard ratio [HR] = 1.76) and cardio-
vascular death (adjusted HR = 3.13) [12]. Conversely, an-
other study using elevated hs-TnT above 99th percentile
reference could not demonstrate a statistical association
with adverse cardiovascular outcome [14]. The contra-
dictory results from these studies may suggest the poten-
tially limited prognostic value of hs-TnT in patients with
T2DM. Because of the different biological characteristics
[26], the clinical relevance and strength of detecting
myocardial injury between hs-TnT and hs-TnI may dif-
fer. Indeed, it has been shown that the prognostic value
of hs-TnI may be superior to hs-TnT in a cohort of pa-
tients with stable coronary artery disease [11]. The prog-
nostic implication of hs-TnI may thus be more robust
than hs-TnT in patients with T2DM.
A prior study demonstrated that a low level of circula-
tory TnI (9 ng/L to 30 ng/L) was predictive of MACE
(death, MI or stroke) in patients with T2DM who under-
went elective coronary angiography [27]. Nonetheless no
study has evaluated the predictive value for MACE using
a high sensitivity assay of TnI (level of detection = 1.2
ng/L). The present study included an expanded and clinic-
ally relevant population, consisting of both male and fe-
male T2DM patients, with and without underlying
cardiovascular disease. Our results demonstrate that ele-
vated hs-TnI independently predicted MACE (adjusted
HR = 2.85) in patients with T2DM, and thus provides fur-
ther evidence that elevated hs-TnI is closely associated
with and predictive for future adverse events in patients
with T2DM.
In this study, the high prevalence of MACE in T2DM
patients with elevated hs-TnI was mainly driven by more
frequent heart failure and cardiovascular death. In con-
trast, an elevated hs-TnI was not associated with future
myocardial infarction. Indeed, prior studies have shown
that among patients with stable chronic cardiovascular
disease, an elevated troponin level better predicts heart
failure than ischemic events [2,4,5,7,11,21]. In the Fra-
mingham Offspring Study, an elevated hs-TnI wasindependently predictive of death, heart failure and
major cardiovascular events, but not coronary heart dis-
ease [7]. Similarly, Omland et al. showed that among pa-
tients with stable coronary artery disease, an elevated
hs-TnI was strongly associated with cardiovascular death
and heart failure but only weakly with non-fatal myocar-
dial infarction [11]. Collectively, these findings support
the hypothesis that a measurable circulating troponin
level reflects chronic myocardial damage/myocardial
stress, rather than acute ischemic insult or vascular
stress. It can thereby identify an increased risk for patho-
logical cardiac remodeling and subsequent heart failure.
In patients with T2DM, a number of mechanisms
might explain the presence of ongoing subtle myocardial
injury, including coronary microvascular dysfunction
[28], depletion of endothelial progenitor cells [9], ele-
vated oxidative stress [9,28], and advanced glycation
end-products [29]. This is further evidenced by a study
that showed that chronic hyperglycaemia, as measured
by HbA1c, was independently associated with subclinical
myocardial injury in subjects without clinically evident
coronary artery disease, as assessed by elevated levels of
hs-TnT [13]. In addition, this study also showed that the
association of HbA1c with hs-TnT extends to subjects
below the diagnostic threshold of 6.5%, and suggests that
hyperglycaemia-related myocardial injury may begin be-
fore the onset of clinically evident diabetes. The circulat-
ing troponin detected by these high sensitive assays in
patients with T2DM thus represents an intermediate
phenotype of subtle myocardial injury, rather than an
acute ischemic event.
In patients with T2DM, a number of different cardiovascu-
lar investigations, including treadmill testing [30], computed
tomography angiography [31] and electrocardiogram-gated
single photon emission computed tomography [32] have
been shown to provide excellent negative predictive
value for future cardiovascular events. Nevertheless
their widespread clinical use for risk stratification is lim-
ited by the need for an experienced operator; prolonged
study duration and prohibitive cost. One of the most in-
triguing findings of the present report was that a normal
hs-TnI had a high negative predictive value for future
adverse cardiovascular events in patients with T2DM
after up to four years of follow-up. The present study
thus suggests that a single serum measurement of hs-TnI
provides a simple and inexpensive means to accurately
risk stratify patients with T2DM, particularly identifying
those at low risk for intermediate-term (>4 years) adverse
cardiovascular events.
Interpretation of both hs-TnI and hs-TnT level can be
done using a cut-off value either above the level of detec-
tion or above the 99th percentile of a reference population
[2]. Even within the same study population, the proportion
of subjects with detectable hs-TnI is greater than hs-TnT
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with T2DM had a detectable hs-TnI, compared with only
45.5% of diabetic women in the Women’s Health Study
using hs-TnT [12]. Further, up to 25% of patients with
T2DM had an elevated hs-TnI defined according to the
99th percentile of an age and gender matched reference
population. This finding demonstrates that hs-TnI is a
sensitive assay to detect subtle myocardial injury, and up
to one quarter of stable patients with T2DM had signifi-
cant myocardial damage. In addition to the prognostic im-
plication, this assay hence can be used as a surrogate for
subtle myocardial injury to further study the mechanism
of myocardial damage in patients with T2DM.
Limitations
The present study included only a small study population
of patients with T2DM and future study with a larger
number of subjects is required to confirm the results.
None of the patients received further coronary work-up
based on the hs-TnI level alone. Future studies should
evaluate the predictive value of significant coronary artery
disease in T2DM patients with elevated hs-TnI. The study
population is Asian, thus it may not be appropriate to ex-
trapolate the results to other ethnic groups. Finally, only a
single measurement of hs-TnI was used for risk stratifica-
tion. Whether serial measurements of hs-TnI would pro-
vide additional information requires further evaluation.
Conclusion
This study demonstrated that elevated hs-TnI was asso-
ciated with MACE, heart failure, myocardial infarction
and cardiovascular mortality in patients with T2DM. In
addition, elevated hs-TnI was independently associated
with MACE and heart failure after multivariate adjust-
ment. Importantly, a single measurement of hs-TnI pro-
vided a high negative predictive value for cardiovascular
outcome in patients with T2DM.
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